Hengrui pharmaceutical 1.1 tumor drug cimetidine obtained clinical approval

According to the information on the website of the State Food and Drug Administration (CFDA) on May 14, the declared clinical status of the 1.1-type chemical raw materials and tablets of Hengrui pharmaceutical was changed to "certificate preparation completed - approved Jiangsu Province" The company said that the clinical status of the drug has been approved Cimetidine is a hedgehog pathway inhibitor, a vismodegib analogue According to the public information, vismodegi was developed by Genentech, a Roche based gene technology company, and was approved by FDA on January 30, 2012 for the treatment of basal cell carcinoma In 2012, the drug achieved sales revenue of US $30.9 million Zhang Lianshan, vice president of Hengrui medicine and President of global R & D, said that cimd had a good effect on solid tumors "Gastric cancer and lung cancer can be used." According to CFDA, only Hengrui medicine has applied for clinical application of cimetidine in China It is worth mentioning that Hengrui medicine is the leader of innovative medicine in China There are many innovative drugs in the field of cardio cerebrovascular and tumor In the past, there have been many class 1.1 new drugs that have been actively selected to stop development due to the market environment and drug efficacy is not obvious, including felotaxay and umideji In response, Zhang Lianshan said that the competition pattern of cimd is good and the company will continue to carry out clinical research on the drug.